Navigation Links
Stallergenes: First Half Year 2008: A 19% Increase in Operating Profit and Net Profit
Date:8/27/2008

ANTONY, France, August 27 /PRNewswire-FirstCall/ -- The Board of Directors, meeting today under the chairmanship of Albert Saporta, approved STALLERGENES' half year consolidated financial statements:

(EUR millions) 2007 HY1 2008 HY1 08/07

% of % of %

sales sales change

Sales 74.8 100.0 87.0 100.0 16

Cost of sales (16.9) (22.5) (19.9) (22.8) 18

Gross profit 57.9 77.5 67.1 77.2 16

General, administrative and selling (31.3) (41.9) (35.1) (40.3) 12

expenses

Gross operating profit before R&D 26.6 35.6 32.1 36.8 21

R&D (11.2) (15.0) (13.7) (15.7) 22

EBIT 15.4 20.6 18.4 13.8 19

Net profit (Group share) 10.1 13.6 12.0 13.8 19

Net borrowings 9.3 4.2 (54)

Sales growth and financial position

The first half of 2008 witnessed a marked increase in operating profitability, which benefited from sales growth. Gross profit as a percentage of sales remained stable at 77%.

R&D expenses were up 22%, reflecting the stepped-up allergen tablet development programme.

Operating profit totalled EUR 18.4 million, an increase of 19% that showed a further improvement in operating profit margin to 21.1% of sales.

Net profit concurrently increased by 19% to EUR 12 million.

The financial position improved: net borrowings declined by 54% and now only represent 6% of equity, compared to 17% at end June 2007 (16% at 31 December 2007).

Significant HY1 2008 transactions and events

On 24 June 2008, Stallergenes was granted the mark
'/>"/>

SOURCE Stallergenes
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Stallergenes: Q2 2008 Sales up 18% Revision Upwards of 2008 Sales Growth
2. STALLERGENES: 2007: A Further Year of Strong Growth: Up 16%
3. STALLERGENES: ORALAIR Grasses: Positive Results of VO52.06 Paediatric Study
4. Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
5. States First Single Incision Robotic Kidney Removal Performed at Henry Ford Hospital
6. Huifeng Bio-Pharmaceutical (HFGB) to Attend CPhI South America 2008 Pharmaceutical Conference; The First CPhI Conference to be held in the Emerging Market of Brazil
7. Natures Premium(R) Brand First Fresh Pork in North America to Carry DNA TraceBack(R) Seal of Authenticity
8. Video: CSL Behring Provides $1.2M Grant for Worlds First Study of Postpartum Women with VWD, Common Bleeding Disorder
9. China-Biotics, Inc. Reports First Quarter 2009 Financial Results
10. Huifeng Bio-Pharmaceutical (HFGB) Reports over $5 Million in Gross Sales; Record Results for the First Half of 2008
11. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... SAN DIEGO and HONG KONG ... an innovative rare disease therapeutics enterprise, announced today that ... joined the company as vice president, research. Dr. McKew ... research, including key leadership positions at the National Institutes ... to its acquisition by Wyeth). Dr. McKew will lead aTyr,s ...
(Date:10/20/2014)... /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today ... to $5.8 million and provides a good start to Q4.  The ... America and one in the Middle East ... record levels," said Peter Bruijns , President & CEO. "Total ... Q3 than they have been for any complete year since the ...
(Date:10/20/2014)... Earle Martin , Chief ... that Ellen Teplitzky, an experienced attorney specializing in ... industry, has joined the firm as Director of ... practice. NDA Partners provides legal services, including ... to top law firms and their clients in ...
(Date:10/19/2014)... The Asia-Pacific Bromine Market report defines and ... and forecast of revenue. , Browse through the ... to get an idea of the in-depth analysis ... segmentation in the Asia-Pacific bromine market, and is ... http://www.micromarketmonitor.com/market/asia-pacific-bromine-6741503144.html , Bromine is a volatile ...
Breaking Biology Technology:aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 3
... (Amex: IMA ) today announced that it has ... Australian company traded on,the Australian Securities Exchange, under which ... issued shares in Panbio for AUD 0.65 cash,per share. ... of,Panbio at approximately AUD 41 million, or approximately USD ...
... ExL Pharma, Cision and the PRSA have,joined ... biotech,public relations executives the first Pharmaceutical Public Relations,Symposium ... This,one-day event will cover the key issues and ... is under ongoing political and media scrutiny,most notably ...
... USC,s Increased Commitment to Research Advancements in Health ... Robust Life Science Industry in Los Angeles, LOS ... University of Southern California,s strengthened,commitment to advancing breakthrough research ... today the opening of an office,in the new Harlyne ...
Cached Biology Technology:Inverness Medical Innovations Agrees to Acquire Panbio Ltd. 2Leading Pharmaceutical Communication Executives Gather for the 1st Annual Pharmaceutical Public Relations Symposium 2The USC Stevens Institute for Innovation Opens Shop on US Health Sciences Campus 2The USC Stevens Institute for Innovation Opens Shop on US Health Sciences Campus 3The USC Stevens Institute for Innovation Opens Shop on US Health Sciences Campus 4
(Date:10/17/2014)... regarding Ebola is critical and pertinent for practicing physicians ... outbreak and epidemic. The Journal, Disaster Medicine and ... Ebola Virus and Public Health, to surround the public, ... critical societal moment. , On October 17, the ... . The primer was prepared by Dr. Eric Toner, ...
(Date:10/17/2014)... the University of Copenhagen have shown for the first ... of Cystic fibrosis patients, giving them the opportunity to ... chronic infections. , The study also discovered the bacterial ... patients was halted or slowed down by the immune ... the oxygen and helped "suffocate" the bacteria, forcing the ...
(Date:10/16/2014)... human body. Battles are won, lost or sometimes ... stalemate—known as tumor dormancy—can last up to 25 ... is poorly understood. , A new computational ... a Professor of Chemistry at Princeton University, may ... the switch to a malignant state. Published today ...
Breaking Biology News(10 mins):Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2Modeling tumor dormancy 2
... WHITE PLAINS, N.Y. MAY 28, 2009 -- Starting pregnancy at ... is critical to giving a baby a healthy start in ... new guidelines from the Institute of Medicine (IOM). ... of weight a woman should gain during pregnancy. While the ...
... and Energy Secretary Steve Chu are consistent in their ... biofuels as an alternative to gasoline are coming. While ... has been on global warming, such a shift could ... Biosciences Institute (EBI) has produced a novel and comprehensive ...
... State University engineers have created a non-toxic "wrinkled" coating ... troublesome barnacles during 18 months of seawater tests, a ... dollars in cleaning and fuel costs. The research ... the Department of Chemical and Biomolecular Engineering, and Dr. ...
Cached Biology News:New guidelines to fight obesity in pregnancy issued 2The coming of biofuels: Study shows reducing gasoline emissions will benefit human health 2The coming of biofuels: Study shows reducing gasoline emissions will benefit human health 3The coming of biofuels: Study shows reducing gasoline emissions will benefit human health 4Non-toxic hull coating resists barnacles, may save ship owners millions 2
... Transformation Kit is designed for rapid ... Advantages over commonly used transformation procedures ... methods include:- Cells can be made competent ... cell preparation and transformation solutions are ...
Endomorphin-2. Cross reactivity: Endomorphin-1 3%, Met-enkephalin <0.03%, Leu-enkephalin <0.01% and beta-Endorphin <0.01%....
...
... Error-free cloning of BAC (100+kb), fosmid (40kb), ... insert stability than any othe BAC vector. ... high yields and easy recombinant DNA purification. ... transcription-free (pSMART VC) vectors for the highest ...
Biology Products: